Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) Gross Margin (2022 - 2026)

TriSalus Life Sciences has reported Gross Margin over the past 5 years, most recently at 86.18% for Q1 2026.

  • For Q1 2026, Gross Margin rose 249.0% year-over-year to 86.18%; the TTM value through Mar 2026 reached 85.07%, down 53.0%, while the annual FY2025 figure was 84.57%, 148.0% down from the prior year.
  • Gross Margin for Q1 2026 was 86.18% at TriSalus Life Sciences, down from 86.66% in the prior quarter.
  • Over five years, Gross Margin peaked at 89.83% in Q4 2023 and troughed at 74.71% in Q4 2022.
  • A 5-year average of 84.3% and a median of 84.96% in 2024 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 1512bps in 2023 and later plummeted -455bps in 2024.
  • Year by year, Gross Margin stood at 74.71% in 2022, then rose by 20bps to 89.83% in 2023, then dropped by -5bps to 85.28% in 2024, then grew by 2bps to 86.66% in 2025, then dropped by -1bps to 86.18% in 2026.
  • Business Quant data shows Gross Margin for TLSI at 86.18% in Q1 2026, 86.66% in Q4 2025, and 83.52% in Q3 2025.